Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas

Trial Profile

Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary)
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RRTCLAlloSCT
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.
    • 31 Jan 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
    • 31 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top